Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook

Date: March 22, 2010
Pages: 185
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: G9D4700F84AEN
Leaflet:

Download PDF Leaflet

Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
The key factor in the current scenario for next-generation omics-based diagnostic technologies is the level of accuracy in the results, followed by the capacity to detect early, and cost. Cost currently remains a major constraint, as people and healthcare institutes are skeptical of investing in technologies that have not provided very wide and acceptable results. The impact of cost constraints will diminish as the cost/value benefit is established. The future market will demand reliability, which means reproducible results on standard equipment, and techniques with less deviation across laboratories and methodologies. The importance of accuracy remains constant. Industry participants will continue to position their diagnostic products based on accuracy levels. Emphasis will also remain on its capacity to test the probability of disease as early as possible through a non-invasive method of diagnosis.

The report discusses drivers, restraints, challenges and opportunities and market estimates of the global diagnostics market in genomics, proteomics and metabolomics on the basis of:

  • Technologies
  • Applications
  • Strategic issues and innovations


  • Key features of this report

  • Measures the global diagnostics market with respect to technologies and applications
  • Analyzes the market with respect to drivers, restraints, challenges, opportunities and market estimates
  • Identifies trends and innovations in the markets analyzed
  • Analyzes and forecasts the revenues of regional market segments
  • In-depth analysis of competitive landscape, top-selling products and services


  • Scope of this report

  • Understanding the existing and emerging applications of diagnostic in the three omics technologies of proteomics, genomics and metabolomics.
  • Analyses of the products and technological developments in the market.
  • Understanding of the various applications and their importance in the development of new diagnostics products
  • Many novel tests such as mass spectrometry and microarrays are expected to make a significant difference in the prognosis, monitoring and diagnosis of cancer patients.


  • Key Market Issues

  • Past and current trends are still dominated by symptom based diagnosis.
  • However, current healthcare objectives focus on early detection.
  • The future is about genetic study and disease pre-disposition, which will test the probability of acquiring a disease or a disorder, enabling precautionary steps.
  • Evolving technology development based on omics technologies are making diagnostic tests less expensive.
  • Accuracy remains the key demand for next generation omics based diagnostics.


  • Key findings from this report

  • Mass spectrometry is used to identify potential circulating protein biomarkers for non-small cell lung cancer.
  • Omics and diagnostics have been helpful in the diagnosis of H1N1, but genome-based techniques have proved vital in identifying the strain of the virus.
  • Genome sequencing remains the most challenging task, as it requires a great deal of time and investment.
  • Biomarkers in omics have contributed greatly to the early diagnosis of cancer.


  • Key questions answered

  • What are the existing and pipeline technologies and products in the diagnostics market?
  • What are the major application areas of diagnostics?
  • What are the key market developments of the top companies profiled in this report?
  • What are the trends and innovations in the global diagnostics market?

  • Genomics, proteomics and metabolomics in diagnostics
    Executive summary 14
    Market overview 14
    Biomarkers 14
    Microarrays and microfluidics 16
    Lab-on-a-chip proteomics 16
    Bioinformatics 17
    Emerging applications 18
    Applications market 18
    Competitive landscape 19
    Patent analysis 20
    Geographic analysis 20
    Company profiles 21

    CHAPTER 1 MARKET OVERVIEW

    Summary 24
    Emerging trends focus on survival rates and non-invasive methods 25
    Accuracy remains the key for next generation omics-based diagnostics 26
    Biomarkers setting standards for ideal diagnostic methodology 27
    Key market drivers & resistors 29

    CHAPTER 2 BIOMARKERS

    Summary 32
    Defining biomarkers 33
    The biomarker market 33
    Market drivers 33
    Restraints 35
    Emerging applications of biomarkers 37
    Omics technologies 37
    Disease predisposition 38
    Pre-natal testing 38
    Biomarkers and translational medicine 38
    Proteomics and biomarker applications 39
    Post-genomic biomarker technologies 39
    Innovative technologies provide patient centric data 39
    Genomic technologies play a significant role in nutritional research 40
    Molecular diagnostics 40
    Mass spectrometry (MS) 40
    Gel electrophoresis 41
    Metabolomics 42
    Imaging biomarkers 42
    Confluence of diagnostics and pharmaceutical companies 43
    Challenges 43
    High investment hampers advance biomarker research 43
    Validation challenge 44
    Lack of IT solutions 44

    CHAPTER 3 MICROARRAYS AND MICROFLUIDICS

    Summary 46
    Microarrays and microfluidics 47
    Market drivers 47
    Market restraints 49
    DNA microarrays 51
    Fabrication technologies 51
    Printing with fine-pointed pins onto glass slides 51
    Photolithography using pre-made masks 52
    Ink-jet printing 52
    Analytical methods 52
    mRNA profiling 53
    Genetic imbalance detection 53
    Gene expression profiling 53
    SNP detection 54
    DNA microarrays in in vitro diagnostics (IVD) 54
    Protein microarrays 55
    Protein immobilization strategies 56
    Surface chemistries 56
    Format of protein chips 56
    Complete protein profiling utility 57
    Tissue and cell microarrays 58

    CHAPTER 4 LAB-ON-A-CHIP PROTEOMICS

    Summary 60
    Introduction 61
    Classification of LOCs 61
    Market drivers for LOC 62
    Drawbacks 64

    CHAPTER 5 BIOINFORMATICS

    Summary 66
    Introduction 67
    Market drivers 67
    Market restraints 68
    Applications in diagnostics 70
    Strategic recommendations 72
    Advancements in molecular diagnostics and bioinformatics 73

    CHAPTER 6 EMERGING APPLICATIONS

    Summary 76
    Quantitative real-time polymerase chain reaction (qPCR) 77
    DNA biosensors 78
    Flow cytometry 78
    DNA methylation 79
    Nanotechnology 80
    Other novel diagnostic applications 81
    DNA testing technologies 81
    Mass spectrometry and proteomics 81
    H1N1 82
    Metabolomics and related diagnosis 82
    MicroRNA 83
    Use of protein microarrays for early detection of disease 83
    Next-generation sequencing technologies and IT technologies 84
    Biomarkers 85

    CHAPTER 7 APPLICATIONS MARKET

    Summary 88
    Application by utility 89
    Sequence analysis 90
    Structure analysis 91
    Function analysis 91
    Application by disease 91
    Cancer 92
    Infectious disease 92
    HIV 93
    Autoimmune diseases 93
    Neurological disorders 93
    Cardiovascular and metabolic disease 94

    CHAPTER 8 COMPETITIVE LANDSCAPE

    Summary 96
    Agreements and collaborations 97
    New product/service launches 102
    Mergers and acquisitions 103

    CHAPTER 9 PATENT ANALYSIS

    Summary 106
    Introduction 107
    Patents by technology 108
    Patents by geography 110
    Patents by assignee 112

    CHAPTER 10 GEOGRAPHIC ANALYSIS

    Summary 116
    Global diagnostics market 117
    North America 117
    Europe 119
    Asia 120
    Rest of the World (ROW) 121

    CHAPTER 11 COMPANY PROFILES

    Summary 124
    Affymetrix 125
    Company overview 125
    Products and services 125
    Strategy and developments 126
    Agilent Technologies 126
    Company overview 126
    Products and services 126
    Strategy and developments 127
    Amgen 127
    Company overview 127
    Products and services 128
    Strategy and developments 128
    Beckman Coulter 128
    Company overview 129
    Products and services 129
    Strategy and developments 129
    Bio-Rad Laboratories 129
    Company overview 130
    Product and services 130
    Strategy and developments 130
    BG Medicine 130
    Company overview 130
    Products and services 131
    Strategy and developments 131
    Biophysical Corp 132
    Company overview 132
    Products and services 132
    Strategy and developments 132
    BioSystems International (BSI) 133
    Company overview 133
    Products and services 133
    Strategy and developments 134
    Calibrant 134
    Company overview 134
    Products and services 135
    Strategy and development 135
    Caprion Proteomics 135
    Company overview 135
    Products and services 136
    Strategy and developments 136
    deCODE Genetics 136
    Company overview 137
    Products and services 137
    Strategy and developments 137
    Exagen Diagnostics 137
    Company overview 138
    Products and services 138
    Strategy and developments 138
    GE Healthcare 138
    Company overview 139
    Strategy and developments 139
    Genedata 140
    Company overview 140
    Products and services 140
    Strategy and developments 140
    GeneNews 141
    Company overview 141
    Products and services 141
    Strategy and developments 142
    Human Metabolome Technologies (HMT) 142
    Company overview 142
    Products and services 143
    Strategy and developments 143
    Illumina, Inc. 143
    Company overview 143
    Products and services 144
    Strategy and development 144
    Imgenex 144
    Company overview 145
    Products and services 145
    Strategy and developments 145
    InforSense 145
    Company overview 146
    Products and services 146
    Strategy and developments 146
    Integromics 146
    Company overview 147
    Products and services 147
    Strategy and developments 147
    MDS, Inc. 147
    Company overview 148
    Products and services 148
    Strategy and developments 148
    Metabolon, Inc. 148
    Company overview 149
    Products and services 149
    Strategy and developments 149
    Metanomics Health GmbH 149
    Company overview 150
    Products and services 150
    Strategy and developments 150
    Microchip Biotechnologies 150
    Company overview 151
    Products and services 151
    Strategy and developments 151
    MicroDiscovery 151
    Company overview 151
    Products and services 152
    Strategy and developments 152
    Molecular Connections 152
    Company overview 152
    Products and services 153
    Strategy and developments 153
    NextGen Group PLC 153
    Company overview 153
    Products and services 153
    Strategy and developments 154
    Nonlinear USA, Inc. 154
    Company overview 154
    Products and services 155
    Strategy and developments 155
    Nuvera Biosciences 155
    Company overview 155
    Products and services 156
    Strategy and developments 156
    Ocimum Biosolutions 156
    Company overview 156
    Products and services 157
    Strategy and developments 157
    Pam Gene BV 157
    Company overview 157
    Products and services 157
    Strategy and developments 158
    Siemens Healthcare 158
    Company overview 158
    Products and services 158
    Strategy and developments 158

    CHAPTER 12 APPENDIX

    Patents 160
    Methodology 185

    LIST OF FIGURES

    Figure 1.1: Evolving trends in diagnostics 25
    Figure 1.2: Key features of next generation omics-based diagnostic technologies 27
    Figure 2.3: Key market drivers for biomarkers 34
    Figure 2.4: Key market restraints for biomarkers 36
    Figure 3.5: Key market drivers for microarrays & microfluidics 48
    Figure 3.6: Key market restraints for microarrays & microfluidics 50
    Figure 5.7: Key market drivers for bioinformatics 68
    Figure 5.8: Key market restraints for bioinformatics 69
    Figure 5.9: Evolution of bioinformatics 71
    Figure 8.10: Diagnostic companies strategies 97
    Figure 8.11: Recent developments: agreements & collaborations, 2008 - Jan 10 98
    Figure 8.12: Mergers and acquisitions, 2008 - 09 103
    Figure 9.13: Total number of patents registered, 2006–09 107
    Figure 9.14: Patents by technology, 2006-09 109
    Figure 9.15: Patents by geography, 2006-09 110
    Figure 9.16: Patents by geography and technology, 2006–09 111
    Figure 9.17: Patents by assignee, 2008 113
    Figure 10.18: North American diagnostics market ($m), 2007–14 118
    Figure 10.19: European diagnostics market($m), 2007–14 119
    Figure 10.20: Asian diagnostics market($m), 2007–14 121
    Figure 10.21: RoW diagnostics market ($m), 2007–14 122

    LIST OF TABLES

    Table 1.1: Global omics-based diagnostic technology market ($m), 2007-14 28
    Table 2.2: Global biomarker market, by geography, ($m) 2007–14 37
    Table 3.3: Global microarray market, by products, ($m) 2007–14 50
    Table 3.4: Global microarray market, by geography, ($m) 2007–14 51
    Table 3.5: Global DNA microarray market, by geography, ($m) 2007–14 55
    Table 3.6: Global protein microarray market, by geography, ($m) 2007–14 57
    Table 3.7: Global tissue/cell microarray market, by geography, ($m) 2007–14 58
    Table 4.8: Global LOC market, by geography, ($m) 2007–14 64
    Table 5.9: Global bioinformatics market, by geography, ($m) 2007–14 69
    Table 6.10: Global qPCR market, by geography, ($m) 2007–14 77
    Table 6.11: Global DNA biosensors market, by geography, ($m) 2007–14 78
    Table 6.12: Global flow cytometry market, by geography, ($m) 2007–14 79
    Table 6.13: Global DNA methylation market, by geography, ($m) 2007–14 80
    Table 6.14: Global nanotechnology market, by geography, ($m) 2007–14 81
    Table 7.15: Global diagnostics market, by utility, 2007–14 ($m) 90
    Table 7.16: Global diagnostics market, by diseases, 2007–14 ($m) 92
    Table 8.17: Details of recent agreements & collaborations 99
    Table 8.18: Details of recent agreements & collaborations (ctd1) 100
    Table 8.19: Details of recent agreements & collaborations (ctd2) 101
    Table 8.20: Details of recent new product/service/technology launches 102
    Table 8.21: Details of recent M&A activity 104
    Table 10.22: Omics-based diagnostics market, by geography, ($m) 2007-14 117
    Table 12.23: Japanese patents 160
    Table 12.24: Japanese patents (ctd1) 161
    Table 12.25: Japanese patents (ctd2) 162
    Table 12.26: Japanese patents (ctd3) 163
    Table 12.27: Japanese patents (ctd4) 164
    Table 12.28: US patents 165
    Table 12.29: US patents (ctd1) 166
    Table 12.30: US patents (ctd2) 167
    Table 12.31: US patents (ctd3) 168
    Table 12.32: US patents (ctd4) 169
    Table 12.33: US patents (ctd5) 170
    Table 12.34: US patents (ctd6) 171
    Table 12.35: US patents (ctd7) 172
    Table 12.36: US patents (ctd8) 173
    Table 12.37: US patents (ctd9) 174
    Table 12.38: US patents (ctd10) 175
    Table 12.39: US patents (ctd11) 176
    Table 12.40: European patents 177
    Table 12.41: European patents (ctd1) 178
    Table 12.42: European patents (ctd2) 179
    Table 12.43: European patents (ctd3) 180
    Table 12.44: European patents (ctd4) 181
    Table 12.45: European patents (ctd5) 182
    Table 12.46: European patents (ctd6) 183
    Table 12.47: European patents (ctd7) 184
    Table 12.48: European patents (ctd8) 185

    Skip to top


    Ask Your Question

    Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: